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Aim: To assess and compare health status among chronic obstructive pulmonary disease
(COPD) patients presenting for treatment in six countries and in two healthcare settings
using a generic health status instrument.
Methods: A population based cross-sectional survey was conducted among 2703 patients
and their physicians (1381 in primary and 1322 in specialty care) in five EU countries and
the USA. Information was collected on demographic and clinical characteristics,
exacerbations and health status estimated using EQ-5D.
Results: The mean EQ-5D score for COPD patients was similar between primary and
specialty settings in all countries except Italy. Approximately, half of the patients
indicated some impairment in health status on mobility, usual activities, pain/discomfort
and anxiety/depression domains of EQ-5D. Approximately, 5% of patients in EU countries
except UK had health status valued as worse than death based on valuations of the general
population. Patients suffering from severe breathlessness, experiencingX3 exacerbations
in the previous year, categorised as severe according to GOLD criteria, and experiencing
day-time and night-time symptoms had significantly impaired health status.
Conclusion: COPD patients classified as moderate/severe in clinical practice have worse
health status compared to mild patients. This impairment is similar in primary and
specialty setting across western countries.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Chronic obstructive pulmonary disease (COPD) is charac-
terised by a progressive airflow limitation that is not
completely reversible.1 The Global Burden of Disease studies
predicted COPD to become the third most common cause of
mortality and the fourth most common morbidity producing
illness by 2020.2 By the year 2000, COPD became the fourth
leading cause of death which, therefore, indicates that
these projections are likely to be correct.3 Mortality due to
COPD continues to rise in contrast to other chronic diseases
such as coronary artery disease and cerebrovascular disease
where mortality is on the decline.4,5
Although COPD has a considerable burden the disease
appears often to be underdiagnosed and undertreated.1
Traditionally, COPD has not received the same level of
attention as other chronic conditions of similar mortality
and morbidity from decision makers in many countries. The
burden of COPD therefore needs to be highlighted among
patients, physicians and decision makers.6
The burden can be estimated in clinical, humanistic or
economic parameters but COPD being a disease with
multisystemic involvement, humanistic assessment in the
form of health status estimation seems the most appro-
priate.7 Health status can be assessed using either a generic
or a disease specific health status instrument. A number of
generic and disease specific instruments have been used in
COPD, although use of a respiratory specific instrument has
been more common. A generic measure helps healthcare
payers and decision makers to compare health status across
different therapeutic areas to ensure an efficient allocation
of resources between (as well as within) clinical areas. The
EQ-5D is one such generic preference based health status
instrument developed by EuroQol group.8,9 Despite its wide
use in a variety of clinical areas, so far it has been used
sparingly in COPD.10
Several studies have attempted to quantify burden of
COPD in individual countries but no study so far has
compared the health status burden on patients diagnosed
as COPD sufferers across different countries and across
various treatment settings. Comparisons across countries
with different healthcare systems offering varied access to
patients will not only contribute to global assessment of
COPD but may also help in identification of cost effective
forms of COPD management.
The primary objective of this study was to assess and
compare health status using a generic preference-based
instrument in patients diagnosed with COPD presenting for
treatment in six western countries and in two healthcare
settings.
Methods
Study sample and data collection
The Respiratory Disease Specific Programme III (Adelphi
Group Products) was designed to provide key health
outcomes information on an ongoing regular basis. It
included a survey of 328 primary care physicians (PCP) and
335 respiratory specialists (RS) in the USA and five European
countries including France, Germany, Italy, Spain and UK.The study was conducted in the second half of 2003. The
physicians were randomly selected by members of local
research agency in each country from public lists of
healthcare professionals practicing in primary care or COPD
speciality as appropriate. These physicians were represen-
tative of the national population of physicians in terms of
physician’s age, gender and volume of activity, and were
chosen based on the quotas set by speciality type,
geographical location and number of COPD patients cur-
rently being treated by them. The initial stage of recruit-
ment from the randomly selected list of physicians was
through a telephone call to assess their willingness and
eligibility to participate in the study. In the current study
80% of approached candidates agreed to participate.
Physicians who were recruited but who subsequently
dropped out at any stage for any reason before completion
of the study were replaced by randomly selecting physicians
from the initial public lists with similar eligibility to those
who dropped out. In the current study less than 5% of
recruited physicians dropped out and were replaced.
Patient record (PR) forms were placed with the recruited
physicians and the physicians were asked to complete one
PR form per patient on the next six patients diagnosed and
treated for COPD presenting for consultation during the next
10 working days. The identification and selection of patients
was made solely by the physician using following criteria and
was based primarily on the diagnostic judgement and
clinical impression that the physician would use in a normal
clinical practice setting based on signs and symptoms of
COPD. Patients more than 40 years of age with history of
smoking and diagnosis of airflow obstruction (COPD, emphy-
sema and/or chronic bronchitis) were selected irrespective
of their reason for physician visit such as repeat prescrip-
tion, routine review, or an unscheduled consultation. The PR
forms were completed only for the patients personally seen
by the physician either during or immediately after the
consultation by referring to PRs if needed.
Physicians were asked to report the diagnosis given to the
patient and patient’s clinical history in the previous year
including the most recent forced spirometric measure-
ments. In addition, physicians were asked to record the
number of exacerbations suffered by patients in the
previous year. An exacerbation was referred to as an acute
episode where patients received some form of treatment
from the physician but no formal definition for COPD
exacerbation was used. Information was also collected on
patient demographics such as age, gender, body mass index
(BMI), and whether patient lived alone or with someone as
well as comorbidities.
Patients for whom a PR form had been completed were
then asked to complete a separate patient self-completion
(PSC) form by their physicians in clinic immediately after the
physician visit. Representatives of the data collection
agency ensured that patients completed PSC form without
consulting the doctor, nursing staff or any other individual.
PSC form completion by the patient was not obligatory.
Patients who did not complete PSC form (non-responders)
were compared with respondents on demographic and
clinical variables using PRFs filled by their physicians to
eliminate any non-responder bias. This form collected
information on presence of daytime and/or night-time
respiratory symptoms such as cough, wheezing, shortness
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information on breathlessness assessed using Medical Re-
search Council (MRC) dyspnea scale modified by Bestall
et al.,11 current health status assessed using the EQ-5D,8,9
and demographic information such as smoking status and
need for a caregiver to cope with their medical condition.
The information collected using the PSC form was subse-
quently verified by matching with the information obtained
on corresponding PR form wherever possible.
Health status assessment
Health Status was assessed using the EQ-5D self-adminis-
tered questionnaire.8,9 The EQ-5D is a generic, preference-
based measure that provides a single index that represents
overall health status at a point in time. This EQ-5D index
reflects the general public’s valuation (or preference) for an
individual’s health state. The instrument consists of a
descriptive system with five domains which include mobility,
self-care, usual activities, pain/discomfort and anxiety/
depression. Each domain is divided into three levels which
include no impairment, some or moderate impairment and
extreme impairment. These domains and their levels
together define a total of 245 health states (including
unconsciousness and death).
Each of these health states can then be converted into a
single summary index by using the EQ-5D scoring algo-
rithm.12 The scoring algorithm is based on the preferences
of 3395 members of the UK public on a scale where 0 is
equivalent to death and 1.0 is good health. The summary
index referred to as ‘the EQ-5D score’ ranges from 0.594
to 1.0 where negative scores are health states valued as
worse than death by the public. The score of 0.594
represents extreme problems on all the five dimensions and
a score of one represents no impairment on any of the five
dimensions.
Disease severity was estimated for a subset of patients
with spirometric measurements available using GOLD
criteria.1 Patients were classified into GOLD categories
based on post bronchodilator forced expiratory volume in
1 s (FEV1). The survey did not collect information on chronic
respiratory insufficiency (Stages III and IV) as defined by
GOLD guidelines. Therefore the ‘severe’ (GOLD—stage III)
and ‘very severe’ (GOLD—stage IV) subsets were merged to
form a single ‘severe’ subset. Comorbidities were converted
into Charlson index13 and the resultant index was used as an
estimate of the impact of comorbidities on health status.
Statistical analysis
Data from both the PR and PSC forms were extracted and
analysed in the statistical package SPSS (SPSS for Windows,
Rel. 12.0.3. 2003. Chicago: SPSS Inc.). A prior significance
level of 0.05 was used for all statistical tests. Descriptive
analysis was performed on patient demographics, diagnostic
history and health status assessed using the EQ-5D ques-
tionnaire on the entire sample, and then subgroups based on
country and treatment setting. Multivariate analysis was
used to determine the impact of exacerbation frequency,
disease severity, breathlessness and symptoms on health
status after controlling for age, comorbidities, country andtreatment setting using the entire sample. The impact of
above clinical variables on health status was also assessed
separately for either treatment setting after controlling for
age, comorbidities and country. Fischer’s exact and chi-
square tests and, Bonferroni’s correction were used when
necessary.
Results
Three thousand five hundred and eighty three physician
responses out of a possible 3978 patient profiles were
received. The number of profiles reduced to 2933 after
matching physician responses (PR forms) with patient
responses (PSC forms). More than 75% of patients in all the
five countries completed PSC forms and were not signifi-
cantly different than patients who did not complete PSC
form on demographic and clinical variables. Among these
profiles, 230 patients had missing data on EQ-5D and hence
were omitted from the final analysis. This resulted in 2703
usable patient profiles with 1381 patients treated by PCPs
and 1322 patients treated by RSs. The actual numbers of
usable patient profiles are listed in Table 1.
Demographic and clinical characteristics
A comparison of the demographic and clinical character-
istics of patients visiting PCPs and RSs in each country is
summarised in Table 1. When compared across countries,
after controlling for the treatment setting, patients showed
significant differences on all the demographic and clinical
characteristics with the exception of age. When compared
across treatment settings (PCPs vs RSs), after controlling for
the country effect, patients were not significantly different
for obesity based on BMI and the diagnosis of COPD. Overall,
a significantly higher proportion of PCP patients were
females, were current smokers and had received the
diagnosis of chronic bronchitis or emphysema; whereas
significantly higher proportion of RS patients felt the need
for a carer to cope with their condition and were
categorised as moderate or severe according to GOLD
(Po0.05 each). Twenty-nine per cent of patients visiting
PCPs and 32% of patients visiting RSs received the diagnosis
of more than one condition among chronic bronchitis,
emphysema and COPD.
Health status utilities on EQ-5D
The mean EQ-5D scores among respondents in six countries
ranged from 0.62 (France) to 0.71 (USA). Figure 1 displays
the mean EQ-5D scores split between treatment settings in
each country. The scores ranged from 0.65 (France) to 0.73
(Italy) for PCP patients and from 0.60 (France) to 0.71
(Spain) for RS patients. The mean EQ-5D scores for patients
visiting PCPs and RSs were similar in all countries with the
exception of Italy where the PCP scores were significantly
higher (0.73 PCP; 0.62 RS; Po0.01).
Four European countries with the exception of UK had at
least 5% patients (range 5–7%) with an EQ-5D score less than
zero indicating that these patients’ health status was worse
than death as valued by general population on EQ-5D. Less
than 1% patients in UK and 2% patients in the USA had EQ-5D
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Table 1 Patient demographics, clinical characteristics and diagnostic history.
Overall France Germany Italy Spain UK USA
Healthcare setting PCP RS PCP RS PCP RS PCP RS PCP RS PCP RS PCP RS
N 1381 1322 190 183 274 258 181 167 264 275 98 64 374 375
Mean age in years (SE) 66 (0.29) 66 (0.31) 66 (0.86) 64 (0.88) 62 (0.67) 62 (0.75) 64 (0.81) 66 (0.76) 68 (0.59) 67 (0.66) 67 (1.1) 67 (1.1) 68 (0.53) 68 (0.54)
Females % 34y 29y 25 20 33 37 22 22 22z 10z 51 38 49 43
Need carer % 8z 13z 8z 32z 3 5 8 15 13 18 12 16 8 6
Current smokers % 34z 27z 30 33 42 35 26 26 26y 17y 34 26 40z 26z
Clinically obese % (BMIX30) 20 20 15 14 20 17 14 18 18 20 25 16 26 26
Primary diagnosis
Chronic bronchitis % 30y 24y 30 25 42z 22z 28 21 38y 28y 15 19 20 26
Emphysema % 34z 23z 18z 35z 33 31 15 20 14y 25y 19 33 31z 47z
COPD % 84 84 97y 89y 93 90 75y 87y 81 85 74y 92y 78 74
Forced spirometry (N)z 248 872 32 144 68 211 9 41 36 193 22 45 81 238
Mild % 37 25 44 31 34 29 0 42 36 26 50 7 37 18
Moderate % 31 36 31 35 35 37 11 24 31 41 27 29 32 34
Severe % 32 39 25 34 31 34 89 34 33 33 23 64 31 48
PCP denotes primary care physician and RS denotes respiratory specialist.
yPCPs and RSs are significantly different (Po0.01) using Fisher’s exact test.
zPCPs and RSs are significantly different (Po0.001) using Fisher’s exact test.
yPCPs and RSs are significantly different (Po0.05) using Fisher’s exact test.
zThere are significant differences in forced spirometric measurement between PCPs & RSs in Italy (Po0.01), UK (Po0.001) & USA (Po0.01) and overall (Po0.01) using w2 test.
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Table 2 Patient’s health status.
Healthcare setting
Overall mean (95% CI)
Males
Females
Patients o65 years
Patients X65 years
Exacerbations (95% CI)
No exacerbations
1–2 exacerbations
3 or more exacerbations
Forced spirometry (95% CI)
Mild
Moderate
Severe
MRC dyspneazz (95% CI)
Breathlessness after exercising heavily
Breathlessness when hurrying on level ground
Walk slower than most people of same age
Have to stop for breath even when walking on level ground
Too breathless to leave house
Symptomsyy (95% CI)
No symptoms
Day-time symptoms only
Night-time symptoms only
Daytime and night time symptoms
PCP denotes primary care physician and RS denotes respiratory s
yStatistical significance denotes comparison between different ca
age, comorbidities and country.
zRabin and de Charro10 and Bestall et al.11.
ySignificantly different from other category (Po0.05).
zSignificantly different from other category (Po0.001).
Significantly different from both other categories (using Bonferr
yySevere category significantly different from moderate.
zzThe only non-significant difference is for RSs, between categor
slower than most people of same age’’.
yyFor both PCPs and RSs, the only non-significant differences are b
-0.59
-0.09
0.41
0.91
France Germany Italy* Spain UK USAEQ
-5
D 
Sc
or
es
†
PCPs RSs
Figure 1 Mean EQ-5D scores in Primary Care (PCPs) and
respiratory specialist (RSs) settings. *Po0.01 for PCPs vs RSs.
yHigh scores mean better health.
COPD and patients’ health status 665scores less than zero. The proportion of patients with health
status valued worse than death was similar in both
treatment settings with no significant difference in all
countries except Italy (11% RS vs 3% PCP; Po0.01).
Table 2 summarises the health status scores of patients
at the time of the survey. The overall mean EQ-5D score
was similar in both treatment settings. Females had worse
EQ-5D score than males in RS setting (Po0.05) but were
comparable to males in PCP setting. Patients aged 65 and
above had significantly lower EQ-5D score compared to
patients younger than 65 year in both treatment settings
(Po0.001).
Multivariate analysis showed significant impact of clinical
variables such as exacerbation frequency, spirometry,
breathlessness and presence of day-time and/or night-time
symptoms on health status after controlling for age,
comorbidities, country and treatment setting. When thePCPsy RSsy
EQ-5Dz EQ-5Dz
0.70 (0.68–0.71) 0.68 (0.66–0.69)
0.70 (0.68–0.72) 0.69y (0.67–0.71)
0.69 (0.66–0.71) 0.65y (0.62–0.68)
0.77z (0.75–0.79) 0.72z (0.70–0.75)
0.65z (0.62–0.67) 0.64z (0.62–0.67)
0.78 (0.75–0.80) 0.75 (0.72–0.77)
0.74 (0.72–0.77) 0.73 (0.71–076)
0.61 (0.59–0.64) 0.57 (0.54–0.60)
0.77 (0.73–0.81) 0.68 (0.64–0.72)
0.68 (0.62–0.74) 0.72yy (0.69–0.75)
0.62 (0.56–0.68) 0.64yy (0.61–0.67)
0.88 (0.86–0.90) 0.88 (0.85–0.90)
0.79 (0.77–0.81) 0.79 (0.77–0.81)
0.71 (0.68–0.74) 0.73 (0.70–0.76)
0.59 (0.57–0.62) 0.60 (0.58–0.63)
0.17 (0.11–0.24) 0.29 (0.22–0.35)
0.85 (0.83–0.86) 0.81 (0.79–0.84)
0.69 (0.68–0.72) 0.72 (0.69–0.74)
0.73 (0.65–0.81) 0.69 (0.58–0.80)
0.59 (0.56–0.61) 0.56 (0.53–0.59)
pecialist.
tegories within the same treatment setting after controlling for
oni’s multiple comparison test).
ies ‘‘breathlessness when hurrying on level ground’’ and ‘‘walk
etween night-time only and day-time only.
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analysed separately for PCPs and RSs controlling for age,
comorbidities and country, patients with three or more
exacerbations had significantly lower EQ-5D scores com-
pared with patients with less than three exacerbations in
both treatment settings (Po0.05). Mild PCP patients,
classified according to GOLD’s spirometric criteria, had
significantly higher EQ-5D score than moderate and severe
patients (Po0.05) whereas moderate patients visiting RSs
had significantly higher EQ-5D score than severe patients
(Po0.05). Patients’ health status was also associated with
breathlessness (MRC dyspnea scale). As for patients with
increasing levels of breathlessness, the EQ-5D scores ranged
from 0.88 to 0.17 in PCP cohort and 0.88 to 0.29 in RS
cohort. Patients with higher degree of breathlessness had
lower health status with the exception of one category being
significantly different than another as shown in Table 2
(Po0.05 each). In either health-care setting, patients with
both day-time and night-time symptoms had lower health
status than patients with day-time only symptoms or
patients with night-time only symptoms, both of whom in
turn had lower health status than patients with no symptoms
(Po0.05 each).0%
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Figure 2 Frequency counts of patients visiting PCPs*Health states on EQ-5D
Figures 2 and 3 summarise the descriptive analysis of the
distribution of EQ-5D health states across treatment settings
in different countries. The results suggest that, within each
EQ-5D domain, the distribution of problem levels across the
two settings was similar in each country and was largely
consistent across different countries with few differences.
However, when the responses from all the countries in each
domain were pooled and compared across treatment
settings, it resulted in small yet significant differences.
Compared to the PCP setting, a higher proportion of RS
patients had moderate or extreme mobility problems (58% vs
52%), problems with self-care (29% vs 24%) and usual
activities (56% vs 49%) (Po0.01 each). In contrast, the
distribution of health states between the two settings was
similar for pain/discomfort (56% vs 53%) and anxiety/
depression (43% vs 41%).
Table 3 presents a comparison of EQ-5D health states
between COPD patients and the general population in the
USA, UK and Spain, the only countries where general
population estimates on EQ-5D were available. COPD patients
in all the three countries and both the treatment settingsIta
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Figure 3 Frequency counts of patients visiting RSs* on EQ-5D questionnaire. *Respiratory specialists.
Table 3 Comparison of health states between COPD patients and general population (GnP).
USA14 UK15 Spain15
EQ-5D Domains PCPs RSsy GnPz PCPs RSsy GnPz PCPs RSsy GnPz
Mobility (%)y 60 68 19 64 77 18 49 52 15
Self-care (%)y 19 29 4 27 27 4 28 36 2
Usual activities (%)y 52 62 15 57 66 16 42 49 14
Pain/discomfort (%)z 47 40 41 58 45 33 52 40 45
Anxiety/depression (%)y 44 39 26 46 42 21 37 37 25
Percent of patients with moderate or severe problems visiting PCPs.
yPercent of patients with moderate or severe problems visiting RSs.
zPercent of general population with moderate or severe problems. Values not adjusted for age of the study sample.
ySignificant differences between PCP patients and general population and RS patients and general population in all three countries
(Po0.001 each).
zSignificant difference between PCP patients and general population in USA (Po0.01), UK (Po0.001) and Spain (Po0.05), and
between RS patients and general population in UK (Po0.05).
COPD and patients’ health status 667showed substantial impairment in mobility, self-care, usual
activities and anxiety/depression compared to the general
population (Po0.001 each). A significant impairment onpain/discomfort domain of EQ-5D was also shown by patients
visiting PCPs in the USA (Po0.01), UK (Po0.001) and Spain
(Po0.05), and by patients visiting RSs in UK (Po0.05).
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The EQ-5D was used to assess the health status among COPD
patients in this study. EQ-5D is a generic quality of life
instrument with good validity and reliability but has so far
been rarely used to assess quality of life in COPD patients.16
One of the important findings of this study was that the
health status among COPD patients was largely similar in
primary care and specialty treatment settings with few
exceptions. In both treatment settings, the mean EQ-5D
score was similar and the proportion of patients having
health status valued worse than death was comparable in all
countries except Italy. The impact of clinical characteristics
was also similar across treatment settings after controlling
for country effect.
These findings seem largely consistent with the COPD
severity of the patients in these treatment settings. Results
from a small subset of population where spirometric values
were available suggested that patients visiting PCPs and RSs
in France, Germany and Spain were similar on disease
severity. Similar pattern of results were not observed for the
remaining countries. However, availability of spirometric
results for a small proportion of patients and large
differences between numbers of patients with spirometry
results in two treatment settings could be some of the
reasons for this discrepancy.
This however does not undermine the health status
burden on COPD patients. At least 5% of patients in four
European countries except UK had EQ-5D values less than
zero. These patients had a health status valued worse than
death by the general population and the results were
consistent across all four countries and both treatment
settings. Similarly, comparison of EQ-5D health states of
these patients with general population in the USA, UK and
Spain suggested significant impairment in their ability to
walk, take care of themselves and perform routine
activities. Once again, the results were consistent across
all the three countries and both treatment settings. This not
only highlights the detrimental impact of COPD on their
health status but also suggests a need for better COPD
management.
In the present study, parameters used to assess the
severity of COPD patients in clinical practice showed
significant associations with EQ-5D score. These parameters
included objective assessment such as spirometry and
symptomatic assessments such as exacerbation frequency,
breathlessness and presence of respiratory symptoms. COPD
patients who could be classified as moderate to severe
based on these parameters had worse health status than
mild patients in both treatment settings. This highlights the
significant decrease in health status from mild patients to
moderate or severe patients detected even by a generic
health status instrument such as EQ-5D.
Few other studies have previously estimated the impact
of COPD on patients’ health status using EQ-5D.17,18 Stavem
and Jodalen estimated EQ-5D health states of COPD patients
in their study aimed to test and validate a health status
measure in COPD population.17 Out of 52 patients assessed
in their study, none had extreme impairment on mobility
and personal care, 8% patients had extreme impairment in
their usual activities, 4% were suffering from extreme pain/
discomfort and 6% had extreme anxiety/depression. Ourresults are therefore similar with the proportion of patients
having extreme problems on EQ-5D domains being 2% on
mobility and personal care, 6% on usual activities, 5% on
pain/discomfort and 6% on anxiety/depression. In another
study Brazier and others assessed health status of 255 COPD
patients in a teaching hospital in Sheffield, UK.18 The overall
EQ-5D score was 0.54 (standard deviation ¼ 0.309) with a
minimum score of 0.349. In our study the mean EQ-5D
score was 0.67 and the minimum EQ-5D score was 0.07
among 162 UK respondents. COPD patient in our sample
tended towards having better EQ-5D mean and higher EQ-5D
minimum score. However, this was expected considering
that our study was conducted in an outpatient setting with
approximately half of the patients in primary care. There-
fore, our sample may consist of higher proportion of mild
patients compared to the population assessed by Brazier and
others.18
The present study had several limitations. The objective
of the study was to assess health status among COPD
patients visiting PCPs and RSs. However, the study sample
consisted of 18% patients in primary care and 66% patients in
specialty setting with any traceable history of spirometric
measurements and therefore could truly be considered as
patients suffering from COPD. Yet, all the patients included
in the sample received the diagnosis of COPD, chronic
bronchitis or emphysema and were being treated accord-
ingly by their physicians in both treatment settings. Hence
although the results reflect a true practice setting they may
be restricted to the patients diagnosed and treated as COPD
sufferers in the countries and treatment settings included in
the study. Any generalisation of the results beyond the
countries and treatment settings studied would therefore
warrant caution. The study was conducted in several
western European countries and the USA having fairly
advanced health-care systems and access to better COPD
management and treatment. Accordingly, extrapolation of
our results to other countries needs to be tempered.
Although the survey was an enhanced version of the previous
Disease Specific Program surveys (DSP I and DSP II), no pre-
test was conducted. The sample comprised of patients in
physician’s offices and therefore restricts the generalisa-
bility of the study findings to COPD patients presenting for
treatment. The present study used a cross-sectional study
design. The health status assessment therefore represents
the health status of patients at the time of a physician visit.
However, the clinical parameters with the exception of
breathlessness were recorded at some time during the
previous year and therefore may have varying impact on
patients’ health status.
In conclusion, the current analysis of general health in
COPD patients showed clear similarities of impairment
across health care settings. In both treatment settings
moderate to severe patients classified based on various
clinical parameters showed worse health status burden
compared with mild patients. Treatment settings had
minimal impact on health status with patients in primary
care and specialty settings sharing similar health status
burden in most of the countries. Patients with COPD have
significant health status burden especially in their mobility
and their ability to conduct daily activities compared to the
general public. This health status burden is significant even
when valued using societal preferences.
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